title: Localized lymphoid relapse in the pancreas following allogeneic hematopoietic stem cell transplant for chronic myelogenous leukemia.
abstract: The incidence of isolated extramedullary disease (EMD) following allogeneic hematopoietic stem cell transplant (allo-HSCT) for chronic myelogenous leukemia (CML) is not fully known. One review found the incidence of isolated myeloid EMD, or granulocytic sarcoma (GS), in an allo-HSCT treated CML/myelodysplastic subgroup to be just 0.22%. The incidence of lymphoid EMD in similar patients is extremely rare with only two cases reported in the literature. While the etiology of EMD in the post-transplant setting is not entirely clear, there may be inefficacy of immune surveillance function outside of the bone marrow cavity. Isolated CML GS following allo-HSCT carries a median interval to bone marrow relapse between 7 and 10 months and a median survival of 12 months. Less is known about lymphoid EMD. The treatment in these cases is ill defined with modalities ranging from involved field radiation to second allo-HSCT. We present a case of isolated pancreatic lymphoid EMD diagnosed 15 months after allo-HSCT for CML. Our patient was also treated with withdrawal of his immunosuppressive regimen. Unfortunately, at just over 4 months following pancreatic resection, he developed systemic relapse and died. While EMD can occur anywhere in the body, CML associated pancreatic EMD is not previously reported.
authors.affiliation: Western Pennsylvania Cancer Institute, The Western Pennsylvania Hospital, 4800 Friendship Avenue, Suite 2303, Pittsburgh, PA 15224, USA. jrossett@wpahs.org
authors.forename: J M
authors.initials: JM
authors.lastname: Rossetti
authors.forename: J
authors.initials: J
authors.lastname: Lister
authors.forename: R K
authors.initials: RK
authors.lastname: Shadduck
authors.forename: E
authors.initials: E
authors.lastname: Bloom
authors.forename: S J
authors.initials: SJ
authors.lastname: Geyer
authors.forename: P F
authors.initials: PF
authors.lastname: Caushaj
authors.forename: J
authors.initials: J
authors.lastname: Homann
authors.forename: P
authors.initials: P
authors.lastname: Papasavas
authors.forename: M
authors.initials: M
authors.lastname: Cedar
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001854:Bone Marrow Cells / Q000473:pathology; D017809:Fatal Outcome; D006086:Graft vs Host Disease / Q000473:pathology; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D010180:Pancreatectomy; D010182:Pancreatic Diseases / Q000209:etiology* / Q000473:pathology / Q000601:surgery; D012008:Recurrence; D033581:Stem Cell Transplantation / Q000009:adverse effects*; D014184:Transplantation, Homologous / Q000009:adverse effects
chemical_list: D000305:Adrenal Cortex Hormones; D007166:Immunosuppressive Agents